TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating.
Stocks · News reference
ADARx Pharmaceuticals reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline and recent financing activities.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
TD Cowen analyst Tyler Van Buren initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating.
JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
Analysts initiated bullish coverage on ADRX ($32), NWSA ($35), MOD ($275), SITM ($750) and QSR ($85), with Overweight, Outperform or Buy ratings.
UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.
Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.
Filed: 2026-09-28 AccNo: 0001193125-26-405297 Size: 193 KB Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits